CytomX Therapeutics (CTMX) was downgraded by
Weiss Ratings from "hold (c-)" to "sell (d)".
CytomX Therapeutics (CTMX) had its price target raised by Barclays PLC from $10.00 to $16.00. They now have an "overweight" rating on the stock.
CytomX Therapeutics (CTMX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level [Seeking Alpha]
CytomX Therapeutics (CTMX) had its price target raised by Guggenheim from $10.00 to $15.00. They now have a "buy" rating on the stock.